Absolute lymphocyte count predicts therapeutic efficacy and survival at the time of radioimmunotherapy in patients with relapsed follicular lymphomas
Radioimmunotherapy (RIT) delivers radiation to tumor cells using antibodies as carriers of radionuclides. There are two radioimmunoconjugates that have been approved for use in B-cell non-Hodgkin lymphoma -131 I-tositumomab (Bexxar, GlaxoSmithKline, Research Triangle Park, NC, USA) and 90 Y-Ibritumomab tiuxetan (Zevalin, BiogenIdec, Cambridge, MA, USA). 1 Besides the cytotoxic radiation delivered to the tumor cells via antibody binding to a tumor-specific or tumorassociated antigen, several immunologic-related mechanisms have been attributed to RIT, including complement-mediated lysis (complement-dependent cytotoxicity (CDC) and antibodydependent cellular cytotoxicity (ADCC)). 1 Peripheral blood absolute lymphocyte count (ALC) recovery following autologous stem cell transplantation has been reported to be an independent prognostic factor for survival in various hematologic malignancies. 2 Recently, ALC before rituximab therapy was reported to predict better response rates and clinical outcomes in patients with follicular lymphomas (FL) treated with singleagent rituximab. 3 The role of ALC before RIT has not been evaluated previously. We hypothesized that the presence of a competent immune system would translate into a better response and longer survival to RIT.
We evaluated 75 consecutive patients with FL treated with 90 Y-Ibritumomab tiuxetan between 1996 and 2002 at our institution. Fifty-six of these patients had participated in registrational trials and the results of tumor response and toxicity (but not related to ALC) are included in previous publications. 4 Rituximab-refractory patients were classified as patients who did not respond or relapsed within 6 months of rituximab therapy before ibritumomab tiuxetan therapy. All patients were treated with 90 Y ibritumomab tiuxetan 0.4 mCi/kg (maximum of 32 mCi) as described previously. 4 ALC was obtained from the standard complete blood cell count and white blood cell differential before 90 Y-Ibritumomab tiuxetan therapy. 5 No patient refused permission for their medical records to be reviewed for research. Approval for the retrospective review of these records was obtained from the Mayo Clinic Institutional Review Board and was in accordance with US federal regulations and the Declaration of Helsinki.
The objectives of this study were to determine the association between pretreatment blood ALC and complete response (CR) to 90 Y-Ibritumomab tiuxetan, and to assess the impact of pretreatment ALC on overall survival (OS) and progression-free survival (PFS) after 90 Y-Ibritumomab tiuxetan. None of the patients were lost to follow-up.
The characteristics of the 75 patients are summarized in 9 /l, Po0.002, respectively). Receiver operating character and sensitivity/specificity curves and area under the curve (AUC) analysis showed that ALC was a significant marker for CR (AUC ¼ 0.76, Po0.002). Analysis of different cut points of the ALC between the 25 and 75% quartiles (0.23-2.76 Â 10 9 /l) using the log-rank test determined an ALCX1.0 Â 10 9 /l as the cut-off point yielding the highest difference in survival by w 2 (OS, w 2 ¼ 4.1, Po0.04; and PFS, w 2 ¼ 7.3, Po0.007). Therefore, this cut-off value for ALC was subsequently used in univariate and multivariate analyses.
The overall response rate (ORR) for the cohort was 89% (67/75) with 39% (29/75) CR, 51% (38/75) PR, 6% (5/75) stable disease and 4% (3/75) progressed without ever responding. Of the 32 patients with an ALCX1 Â 10 9 /l, 66% (21/ 32) achieved a CR compared with only 19% (8/43) of patients with an ALCo1 Â 10 9 /l, (Po0.0003). Other significant factors for CR in the univariate setting included number of extranodal disease sites (Po0.01) and age (Po0.0004). When these factors were included with ALC in the multivariate logistic regression model, ALCX1 Â 10 9 /l remained a significant predictor of CR with an adjusted odds ratio of 8.6 (95% CI, 2.7-31.6, Po0.001).
The median follow-up was 36.6 months (range: 5.3-99 þ months). The median PFS for the entire cohort was 6.5 months (range: 1-99 þ months). At the time of this analysis 56 (75%) of the patients had documented progression after /l compared with those patients with an ALCo1 Â 10 9 /l (median OS: 84.6 vs 44.7 months, OS rates at 5 years, 65 vs 32%, Po0.04, respectively; and median PFS: 12.4 vs 6.5 months; PFS rates at 5 years, 35 vs 5%, Po0.007, respectively). In the ALCX1.0 Â 10 9 /l group, 44% (14/32) of FL patients achieved a PFSX12 months compared to only 16% (7/43) in the ALCo1.0 Â 10 9 /l group (Po0.02). Twenty-seven patients (36%) were classified as rituximab refractory before 90 Y-Ibritumomab tiuxetan therapy. Rituximabrefractory patients presented with an ALCX1.0 Â 10 9 /l (N ¼ 11) experienced a superior PFS compared to those who did not (N ¼ 16) (median PFS: 17.1 vs 5 months, respectively, Po0.003).
The ALC as a continuous (OS, HR ¼ 0.451, Po0.03; and PFS, HR ¼ 0.448, Po0.007) or dichotomized variable using-X1.0 Â 10 9 /l (OS, HR ¼ 0.697, Po0.04 and PFS, HR ¼ 0.684, Po0.007) was identified as a predictor for survival (Table 2 ). ALCX1 Â 10 9 /l retained statistical significance in the model along with Follicular Lymphoma International Prognostic Index, disease bulk, number of earlier treatments before RIT and 90 Y-Ibritumomab tiuxetan dose (Table 3) . ALC as a continuous variable (OS, HR ¼ 0.486, Po0.04 and PFS, HR ¼ 0.430, Po0.006) also remained a significant factor for survival.
In this study, we demonstrated that the pretreatment ALC is an important predictor of CR and survival in patients with relapsed FL treated with RIT. The ORR and CR rates to RIT in this study are in accordance with previous reports. 4 However, the results of this study indicate that in relapsed FL patients with a higher ALC at the time of 90 Y-Ibritumomab tiuxetan therapy correlated with higher CR (66%) compared to previous studies (CR range: 15-49%). 4 Age, specifically younger patients, was also a predictor for CR, but it did not translate to better OS and PFS. Younger patients in this study presented with lower ALC most likely due to the fact that younger patients received more fludarabine-based regimens (age o60 (32%) vs ageX60 (13%), Po0.04) leading to more lymphopenia before 90 Y-Ibritumomab tiuxetan. Thus, even though younger patients were able to achieve a CR from 90 Y-Ibritumomab tiuxetan, they did not have a robust immune system to sustain long-term response to translate to better survival. ALC remained an independent predictor of CR after Y-Ibritumomab tiuxetan therapy, we investigated if pretreatment ALC also affected survival after RIT. The ALC was an independent predictor for OS and PFS. Even in patients classified as rituximab refractory, those patients with higher ALC experienced a superior PFS compared with those with a low Table 1 Patients' baseline characteristics based on ALCX A limitation of the study is the lack of lymphocyte subsets analysis at the time of 90 Y-Ibritumomab tiuxetan therapy to identify the lymphocyte component conveying the superior survival. However, ALC, as a surrogate marker of immune status, was a predictor not only of response but also of survival. A potential confounding factor of the prognostic ability of ALC in patients with FL is the presence of malignant B-cells in the peripheral blood that could spuriously increase the number of ALC. This is unlikely to be a factor in this study because increased ALC was associated with a better prognosis and increased circulating malignant cells would likely lead to a poorer prognosis.
This study shows superior survival in FL patients who presented with higher ALC numbers at the time of 90 Y-Ibritumomab tiuxetan therapy, suggesting the important role of the host immune system in this setting. ALC as a simple, inexpensive, standardized test predicts not only tumor response, but also the survival after RIT. The ALC should be used as a stratification factor in future randomized treatment trials and may assist clinicians in counseling patients regarding their prognosis. imab Letters to the Editor
